Since estrogen (E2) has been ascribed neuroprotective properties [1–3], we sought to explore if selective activation of the estrogen receptor beta (ERβ, Esr2 gene product), a more clinically relevant target than ERα, can be protective against amyloid-related pathology in the AppNL−G−F mouse model of AD. Here, ESR2 is linked to Alzheimer disease.